Lexicon Pharmaceuticals Releases Positive Clinical Trial Results and Facebook Plans Mobile Payment Services

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) announced positive, top-line results in a Phase 2 clinical trial of LX4211 in type 1 diabetes. LX4211 is an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) that is designed to lower blood glucose levels through two insulin-independent mechanisms of action. The trial achieved the primary endpoint of reducing mealtime insulin use as well as several secondary endpoints, including improved glycemic control.   Lexicon is a biopharmaceutical company focused on developing breakthrough treatments for human